

RNS | 3 June 2024



Immupharma PLC
("Immupharma" or the "Company")

Realisation of c£1.5 million on sale of shares in Incanthera plc

Immupharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, announces that it has realised gross proceeds of c£1.5 million on the sale of its entire holding of c9.9 million shares in Incanthera plc.

Following this transaction, Immupharma retains c7.3 million warrants in Incanthera plc which have an exercise price of 9.5p and exercise expiry date of 6 September 2024.

For further information please contact:

Immupharma PLC (www.immupharma.com)
Dr Tim Franklin, COO
Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650

+ 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin

+44 (0) 203 368 3550

Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob Pountney

+44 (0) 203 650 3650/51

SI Capital (Joint Broker)
Nick Emerson

+44 (0) 1483 413500

Notes to Editors

About Immupharma PLC

Immupharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class autophagy immunomodulator for the treatment of Lupus and CIDP and preclinical analysis suggests P140 may have therapeutic benefit in many other autoimmune diseases that are caused by the same dysfunction in the immune system.

For additional information about Immupharma please visit www.immupharma.co.uk

Immupharma's LEI (Legal Entity Identifier) code : 213800VZKGHC7VUS895.

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DISFIFIARVIVIIS